Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco...
Castle Biosciences, Inc. - Common stock (CSTL)
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm
Check Earnings Report
Company Research
Source: Business Wire
Study shows a 25% reduction in unnecessary sentinel lymph node biopsy (SLNB) procedures performed when patient’s DecisionDx-Melanoma test results were integrated into clinical decision-makingAmong patients electing to have an SLNB, no positive nodes were identified among those with low-risk DecisionDx-Melanoma test results (i.e., predicted sentinel lymph node (SLN) positivity risk of less than 5%), supporting use of the tests’ results to safely inform decisions to forego the procedure FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the latest data from its prospective, multicenter DECIDE study exploring the impact of integrating DecisionDx-Melanoma test results into SLNB decision-making for patients recently diagnosed with melanoma. The updated findings demonstrate the power of the test’s results to accurately identify patients with a low risk of metastasis who
Show less
Read more
Impact Snapshot
Event Time:
CSTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSTL alerts
High impacting Castle Biosciences, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CSTL
News
- New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio [Yahoo! Finance]Yahoo! Finance
- New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology PortfolioBusiness Wire
- What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing? [Yahoo! Finance]Yahoo! Finance
- Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Robert W. Baird from $36.00 to $37.00. They now have an "outperform" rating on the stock.MarketBeat
- Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results [Yahoo! Finance]Yahoo! Finance
CSTL
Earnings
- 2/27/25 - Beat
CSTL
Sec Filings
- 3/12/25 - Form 4/A
- 3/11/25 - Form 4
- 3/7/25 - Form 144
- CSTL's page on the SEC website